Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population

日本人群中具有胰腺癌/乳腺癌/卵巢癌/前列腺癌个人或家族病史的胰腺癌患者的种系 DNA 损伤修复基因突变

阅读:216
作者:Tatsuo Hata, Masamichi Mizuma, Fuyuhiko Motoi, Masaharu Ishida, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Toru Furukawa, Michiaki Unno

Aim

Cancer patients with personal/family histories of pancreatic/breast/ovarian/prostate cancer are associated with a higher likelihood of harboring DNA damage repair (DDR)-related germline mutations. Here, we aimed to obtain a better understanding of DDR-related germline mutations in Japanese pancreatic ductal adenocarcinoma (PDAC) patients with personal and/or family histories of BRCA-related cancers of the pancreas, breast, ovary, and prostate.

Conclusions

A significant fraction of PDAC patients with personal/family histories of BRCA-related cancers harbored deleterious germline mutations in DDR-related genes. DDR-related germline gene mutations might be a favorable prognostic factor in patients with pancreatic cancer.

Methods

We performed next-generation sequencing (NGS) and evaluated germline mutations in nine DDR-related genes (BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, and PMS2) in PDAC patients with personal and/or family histories.

Results

Of 196 patients with PDAC, 39 (19.9%) fulfilled the criteria for at least one family history of pancreatic/breast/ovarian/prostate cancer in first-degree relatives (sibling-sibling or parent-child) or the personal history of these malignancies. Targeted NGS revealed that four (10.2%) of 39 patients with personal/family histories harbored deleterious germline mutations-two in BRCA2, one in ATM, and one in MLH1. Both the BRCA2 variants showed frameshift mutations due to short insertion/deletions. In the 39 patients undergoing NGS, a similar distribution of the clinicopathological characteristics was observed between those with deleterious mutations/variants of unknown significance (VUSs) and with benign/wild types. Patients with deleterious germline mutations/VUSs in DDR-related genes showed a significantly more favorable prognosis than those with benign mutations/wild-type genes (hazard ratio: 0.160, P = .040). Conclusions: A significant fraction of PDAC patients with personal/family histories of BRCA-related cancers harbored deleterious germline mutations in DDR-related genes. DDR-related germline gene mutations might be a favorable prognostic factor in patients with pancreatic cancer.

文献解析

### 前端技术动态:Vue 3.6 与 Vite 重大更新情报  

#### 一、核心动态概览  

尤雨溪宣布 Vue 3.6 将与 Rolldown 深度捆绑,同时 Vite 构建工具将基于 Rolldown 进行彻底重写,标志着前端构建生态进入新阶段。该更新聚焦性能优化与工具链统一,预计将对 Vue 开发流程产生深远影响。  

#### 二、Vite 重写与 Rolldown 集成详情  

1. **技术背景与痛点**  

  - Vite 目前依赖 esbuild(预打包依赖)和 Rollup(生产打包),导致开发与生产环境工具链不一致,调试成本高且性能存在冗余。  

  - Rolldown 是基于 Rust 开发的现代化打包工具,定位为 Rollup 的升级版,具备高性能、兼容性强、优化能力突出的特点。  

2. **Rolldown 核心优势**  

  - **速度**:Rust 底层实现,处理数万模块无压力,性能远超 JavaScript 打包工具。  

  - **兼容性**:支持 Rollup 插件生态,现有项目迁移成本低。  

  - **优化特性**:集成高级分块控制、模块热替换(HMR)、模块联邦等功能,覆盖 esbuild 和 Rollup 的能力并扩展新特性。  

3. **Vite 整合 Rolldown 的目标**  

  - **统一工具链**:将预打包与生产打包流程统一交由 Rolldown 处理,简化架构。  

  - **性能提升**:利用 Rust 底层优化,降低构建耗时,尤其适合大型项目。  

  - **特性增强**:引入 Rolldown 独有的优化能力,提升产物质量与开发体验。  

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。